Genelux Corp. GNLX 深 滬
交易中 07-22 10:11:03 美东时间
3.47
-0.040
-1.14%
華盛通- 最 高3.615
- 今 開3.54
- 成交量 4.30万股
- 最 低 3.47
- 昨 收 3.51
- 總市值 1.31亿
- 52周最高 5.885
- 市盈率 靜 --
- 換手率 0.11%
- 52周最低 1.60
- 委 比 -19.35%
- 總股本 3773.50万
- 歷史最高 40.98
- 量 比 4.00
- 振 幅 4.13%
- 歷史最低 1.60
- 每 手 1
- 風險率 4.83%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅23.77%！美国运通获德银升目标价至375美元，维持"买入"评级
今日重点评级关注：德银：维持美国运通"买入"评级，目标价从371美元升至375美元；巴克莱：维持Gaming and Leisure Props"标配"评级，目标价从54美元升至55美元
今天 09:35
LUCID CAPITAL MARKETS Initiates Coverage On Genelux with Buy Rating, Announces Price Target of $10
LUCID CAPITAL MARKETS analyst Christopher Liu initiates coverage on Genelux (NASDAQ:GNLX) with a Buy rating and announces Price Target of $10.
今天 01:35
Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development
<p>Genelux Corporation has appointed Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer, and Head of Business Development. Groen brings over two decades of experience in life sciences, including roles at Rani Therapeutics and Amgen, where he was involved in major transactions like Amgen’s acquisition of Onyx Pharmaceuticals. His expertise in legal, corporate law, mergers and acquisitions, licensing, compliance, and busin...
07-07 11:00
Benchmark Maintains Speculative Buy on Genelux, Lowers Price Target to $23
Benchmark analyst Bruce Jackson maintains Genelux (NASDAQ:GNLX) with a Speculative Buy and lowers the price target from $25 to $23.
05-08 22:04
Genelux GAAP EPS of -$0.21
Genelux press release (NASDAQ:GNLX): Q1 GAAP EPS of -$0.21. Cash, cash equivalents and short-term investments were $35.1 million as of March 31, 2025. More on Genelux Seeking Alpha’s Quant Rating on ...
05-07 21:53
Benchmark Co. Remains a Buy on Genelux Corp. (GNLX)
In a report released today, Bruce Jackson from Benchmark Co. maintained a Buy r...
04-08 19:35
美股大行评级 | 潜在涨幅592.64%！Larimar Therapeutics获HC Wainwright升目标价至16美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1111574370732224512.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Larimar Therapeutics(LRMR)"买入"评级，目标价从15美元升至16美元</p> <p>• HC Wainwright & Co.：维持Au
03-26 08:45
Genelux prices 3M shares at $3.50 in underwritten public offering
Genelux (NASDAQ:GNLX) has announced the pricing of an underwritten offering of 3M shares of its common stock at an offering price of $3.50 per share. The gross proceeds to Genelux from the offering ar...
03-25 20:48
Genelux Concluded Meeting With FDA For Oli-Vec In Treatment Of PRROC
In response to a question seeking the FDA's guidance on their expectations regarding a confirmatory trial using the ongoing OnPrime/GOG-3076 trial, the FDA responded that "As stated previously, an interim analysis of
03-25 20:34
Genelux names Matthew Pulisic as CFO
Genelux (NASDAQ:GNLX) said it has appointed Matthew Pulisic as its new CFO. Pulisic has over 19 years of experience, and most recently, served as the vice president of finance at Arrowhead Pharmaceuti...
02-03 20:07
